BackDiaMedica Therapeutics Overview

DiaMedica Therapeutics Other Liabilities

Latest other liabilities for DMAC: $0.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

DiaMedica Therapeutics Other Liabilities History

Loading

DiaMedica Therapeutics vs. peers: Other Liabilities Comparison

Loading

DiaMedica Therapeutics Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

DiaMedica Therapeutics (DMAC) FAQ

DiaMedica Therapeutics (DMAC) currently reports a other liabilities of $0 as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore DiaMedica Therapeutics's other liabilities history and peer comparisons.

DiaMedica Therapeutics's other liabilities changed from $0 to $0 (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

DiaMedica Therapeutics reported $0 in other liabilities as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for DiaMedica Therapeutics, and consider following DMAC for alerts when major investors trade the stock.

DiaMedica Therapeutics is classified in the Healthcare sector. On other liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DMAC with unrelated industries.